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ABSTRACT Chronic thromboembolic pulmonary hypertension (CTEPH) is a complication of
pulmonary embolism and a major cause of chronic PH leading to right heart failure and death. Lung
ventilation/perfusion scintigraphy is the screening test of choice; a normal scan rules out CTEPH. In the
case of an abnormal perfusion scan, a high-quality pulmonary angiogram is necessary to confirm and
define the pulmonary vascular involvement and prior to making a treatment decision. PH is confirmed
with right heart catheterisation, which is also necessary for treatment determination. In addition to
chronic anticoagulation therapy, each patient with CTEPH should receive treatment assessment starting
with evaluation for pulmonary endarterectomy, which is the guideline recommended treatment. For
technically inoperable cases, PH-targeted medical therapy is recommended (currently riociguat based on
the CHEST studies), and balloon pulmonary angioplasty should be considered at a centre experienced with
this challenging but potentially effective and complementary intervention.
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Introduction
Since the 5th World Symposium on Pulmonary Hypertension (WSPH) in 2013, major progress has occurred
in the understanding and management of chronic thromboembolic pulmonary hypertension (CTEPH). First,
the link between CTEPH and acute pulmonary embolism, and some of the challenges associated with
making the connection, will be reviewed. Key diagnostic steps in establishing early and accurate diagnosis
will be emphasised. Each component of the current CTEPH treatment approach will be overviewed.
Finally, an updated treatment algorithm is proposed taking into account the advances since 2013.
CTEPH and pulmonary embolism
CTEPH is classified within group 4 PH [1], and is characterised pathologically by organised
thromboembolic material and by altered vascular remodelling initiated or potentiated by a combination of
defective angiogenesis, impaired fibrinolysis and endothelial dysfunction [2–4]. These changes lead to PH
and ultimately right ventricular failure [5, 6]. The precise pathogenesis of CTEPH remains unclear, but
appears to be incited by acute pulmonary embolism [7].
However, classic risk factors for venous thromboembolism do not appear to increase the risk of CTEPH
[8] and there are clear geographic differences in CTEPH epidemiology. An international CTEPH registry
(Europe and Canada) indicated that 75% of patients with CTEPH had a documented antecedent history of
acute pulmonary embolism [9], while in Japan, the rates of acute pulmonary embolism preceding CTEPH
range from only 15% to 33% [10, 11]. There is an 80% female preponderance of CTEPH in Japan; these
statistics differ significantly from the USA and Europe [9]. A number of abnormal autoimmune,
inflammatory and thrombophilia markers have been found in CTEPH patients [2]; it is feasible that
variability in this underlying pathological milieu contributes to the variability in the worldwide CTEPH
epidemiology. Furthermore, variable gene expression has been demonstrated in pulmonary artery
endothelial cells from patients with CTEPH compared with normal controls [12].
In published prospective studies with the diagnosis confirmed by right heart catheterisation (RHC) the
incidence of CTEPH after symptomatic acute pulmonary embolism is reported to range from 0.4% to 6.2%
[13–25], giving a pooled incidence of 3.4% (95% CI 2.1−4.4%) [7]. Since that analysis, a new report from
Switzerland screened 508 patients after acute pulmonary embolism over 2 years and found a cumulative
incidence of CTEPH confirmed with RHC of just 0.79% [26].
Determining the precise CTEPH incidence is complex. CTEPH is likely both underdiagnosed and the
incidence of CTEPH after acute pulmonary embolism prone to overestimation, making the actual
incidence difficult to quantify. Non-specific symptoms, variable rates of antecedent acute pulmonary
embolism and the expertise required to read computed tomography pulmonary angiography (CTPA)
contribute to underdiagnosis [27, 28]. Underdiagnosis is further compounded by the infrequent use of
lung ventilation/perfusion scintigraphy (V/Q scan) despite guideline recommendations [29, 30].
Approximately 30000 acute pulmonary embolism cases are diagnosed annually in France, with the
CTEPH incidence estimated at 3.4% [31]. GUÉRIN et al. [22] suggested a CTEPH incidence of 4.8%.
Neither of these estimates is consistent with the current frequency of newly diagnosed CTEPH. A
limitation of the numerous CTEPH incidence reports after acute pulmonary embolism may be attributed
to an unrecognised amalgam of incident and prevalent cases [22].
In terms of reducing the risk of CTEPH following acute pulmonary embolism, no prospective randomised
acute pulmonary embolism trials have examined systemic or catheter-based thrombolysis or clot extraction
with RHC as an outcome measure in patients with persistent symptoms. Claims have been made that the
incidence of CTEPH in patients receiving thrombolytic therapy is reduced, but end-points such as an
echocardiogram-derived systolic pulmonary arterial pressure (sPAP) of 40 mmHg do not define PH or
CTEPH [32]. Systemic thrombolysis failed to reduce the risk of CTEPH in intermediate/high-risk
(submassive) pulmonary embolism patients in the 3-year follow-up of the PEITHO trial (average sPAP at
follow-up was around 31 mmHg in each group) [33]. To date, there is no proof that aggressive treatment
of acute pulmonary embolism can prevent CTEPH.
Chronic thromboembolic disease
Chronic thromboembolic disease (CTED) is characterised by similar symptoms and perfusion defects, but
without PH at rest. Currently a new threshold for PH (mean PAP (mPAP) >20 mmHg) and pre-capillary
PH (combination of mPAP >20 mmHg, pulmonary arterial wedge pressure ⩽15 mmHg and pulmonary
vascular resistance (PVR) ⩾3 Wood Units) has been proposed by the 6th WSPH Task Force on PH
diagnosis and classification [1]. While there is good evidence to suggest these new thresholds, the
consequences for CTEPH and CTED, respectively, are not yet established. In the future, however, these new
thresholds might also be applied to group 4 PH. Exercise limitation in CTED has been attributed either to
exercise-induced PH, with an increased slope of the pulmonary arterial pressure–flow relationship, or to
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dead-space ventilation, with increased ventilatory equivalents for carbon dioxide [34, 35]. Both new and
worsened dyspnoea and persistent perfusion defects are often encountered after acute pulmonary embolism,
in, respectively, 30% and 30–50% of patients, which makes the recognition of CTED challenging [18, 36, 37].
Cardiopulmonary exercise tests and echocardiographic evaluations are recommended to exclude patients in
whom symptoms are related to lung disease, left heart disease, obesity or deconditioning. A tentative,
comprehensive definition of CTED is proposed in table 1. Selected patients with CTED may benefit from
pulmonary endarterectomy (PEA) as shown in a series of 42 patients out of 1019 who underwent surgery in
the UK reference centre [38]. Post-operative improvement in symptoms, functional class and quality of life
were reported. However, while there was no in-hospital mortality, major complications occurred in 40% of
the cohort (small subdural haematomas, tracheostomy). Although endarterectomy is aimed to prevent
subsequent disease, the natural history of CTED is unknown and there is no evidence that CTED evolves to
CTEPH. At present, patients with CTED represent a group in need of both symptom relief and better
understanding of their disorder. CTEPH treatment guidelines should not be applied to CTED.
Diagnosis of CTEPH
A normal V/Q scan effectively excludes CTEPH with a sensitivity of 90–100% and a specificity of 94–
100% [39, 40]. In a study of confirmed cases of CTEPH, V/Q scan was found to be superior to CTPA with
a sensitivity of 97.4% versus 51% [39]. This difference has narrowed as CT technology and interpretation
have advanced. Indeed, a more recent study has shown that both V/Q scan and CTPA are accurate
methods for the detection of CTEPH with excellent diagnostic efficacy (100% sensitivity, 93.7% specificity
and 96.5% accuracy for V/Q scan; 96.1% sensitivity, 95.2% specificity and 95.6% accuracy for CTPA) [40].
However encouraging, V/Q scan remains the preferred initial imaging test for CTEPH screening [5, 29].
Recent retrospective studies have also assessed the diagnostic accuracy of three-dimensional dynamic
contrast-enhanced lung perfusion magnetic resonance imaging (MRI) against planar V/Q scan or SPECT
(single photon emission CT) scan as a screening tool for CTEPH [41, 42]. These studies demonstrated
that dynamic contrast-enhanced lung perfusion MRI has a similar sensitivity (97%) for diagnosing
CTEPH when compared with planar V/Q scan and a higher sensitivity (100% versus 97%) when compared
with SPECT scan. Prospective studies examining the value of lung perfusion MRI and SPECT scan as a
screening test for CTEPH are required to address the clinical utility (including their costs) and diagnostic
performance of these modalities.
Digital subtraction angiography (DSA) had been considered the gold standard for characterising vessel
morphology in CTEPH, but is being challenged by advances in non-invasive modalities. CTPA is currently
widely used for assessment of operability. CTPA in more recent reports has a high sensitivity and
specificity in detecting chronic thromboembolic lesions at the main/lobar (89–100% and 95–100%,
respectively) and segmental (84–100% and 92–99%, respectively) levels [43–45]. CTPA can also be
valuable by revealing bronchial artery collaterals, which can correlate with more central disease [46], and
by evaluating the lung parenchyma and mediastinum. Advanced CT technologies, including dual-energy
CT (DECT), ECG-gated area detector CT (ADCT), cone-beam CT (CBCT) and contrast-enhanced
magnetic resonance pulmonary angiography, are emerging as valuable modalities for detailing the
pulmonary vasculature. With advances with distal endarterectomy and the advent of balloon pulmonary
angioplasty (BPA), and general focus on more distal vascular assessment, conventional DSA may not
always be suitable for providing fine details. More selective segmental angiography, CBCT and ADCT may
be better for pre-BPA planning by providing greater resolution than conventional DSA, particularly in the
more distal vessels [47]. These imaging techniques are not widely available and require expertise.
TABLE 1 Chronic thromboembolic disease (CTED) compared with chronic thromboembolic pulmonary hypertension (CTEPH)
Diagnostic criteria CTEPH CTED
Symptoms Exercise dyspnoea Exercise dyspnoea
PH Present at rest Absent at rest
RHC at exercise mPAP/CO slope >3 mmHg·L−1·min−1
V/Q scan Any mismatched perfusion defect Any mismatched perfusion defect
Angiography (CTPA or DSA) Typical findings of CTEPH Typical findings of CTEPH
CPET Excluding ventilatory limitation, deconditioning
TTE Excluding left ventricular myocardial or valvular disease
Anticoagulation At least 3 months At least 3 months
RHC: right heart catheterisation; V/Q: ventilation/perfusion; CTPA: computed tomography pulmonary angiogram; DSA: digital subtraction angiogram;
CPET: cardiopulmonary exercise test; TTE: transthoracic echocardiogram; mPAP: mean pulmonary arterial pressure; CO: cardiac output.
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Pulmonary endarterectomy
PEA should be offered to all eligible patients with CTEPH. The international registry of incident cases of
CTEPH reported 3-year survival of 90% in those operated and 70% in those not having surgery [48].
Long-term follow-up of a large cohort reported 10-year survival of 72% (average age 58 years) [49]. Death
was attributed to unrelated causes in 49% of patients; residual PH with PVR ⩾425 dyn·s·cm−5 correlated
with worse survival [49]. Strict objective definitions of operability remain elusive, but certain features are
more likely to predict a good surgical outcome (table 2). While select patients may be technically operable,
they may not benefit from endarterectomy due to significant comorbidities; the best treatment for such
cases remains uncertain. The traditional routine of inserting an inferior vena cava filter (IVC) device prior
to endarterectomy has not been formally studied and has been abandoned at the leading surgical centres.
In the international registry, IVC filter prior to surgery did not influence long-term survival [48].
The most important surgical advance has been in redefining the distal limits of endarterectomy [50, 51].
In expert centres, surgery can be performed successfully in patients with distal chronic thromboembolism
[51]. The advances in diagnostics and growing surgical experience have contributed to this success. As a
result, the previously published intra-operative classification [52] has been refined to better reflect the
current surgical approach and level of revascularisation (table 3) [50]. This also means not all surgical
centres will view operability in the same manner [53]. A three-step stratified definition of expert surgical
centre has been proposed which factors the following important goals: surgical mortality (<5%), surgical
volume (more than 50 PEAs per year) and ability to perform segmental endarterectomy [53].
Furthermore, in this era of a comprehensive approach to CTEPH, an expert centre should be capable of
evaluating and offering any/all established treatment modalities according to individual need.
The place of PH-targeted medical therapy and BPA relative to surgery is dependent on the anatomical
distribution of disease and is not fully defined. Combining endarterectomy with BPA either as a hybrid or
stepwise approach is being evaluated at select expert programmes [54]. In the CHEST-1 study, riociguat
was beneficial for patients with residual PH after endarterectomy [55]. A trial is needed to clarify if
PH-targeted medical therapy prior to endarterectomy in operable patients confers harm or benefit
(ClinicalTrials.gov identifier NCT0327357).
Balloon pulmonary angioplasty
BPA has evolved into an important component of the CTEPH treatment algorithm since the 2012 reports
from Japan [56–58]. BPA has been reported to improve haemodynamics, symptoms, exercise capacity and
right ventricular function, with significantly lower rates of major complications than compared with the
report from 2001 [59–62]. In retrospective analyses, the benefits of BPA also appear to be maintained in
the medium term [10, 63]. Subsequent publications from Europe report similar results [64–66]. The recent
BPA series from Germany is unique as these centres started BPA alongside a well-established PEA
programme [67]. Although their complication rates were similar to those from Japan, the magnitude of
efficacy (e.g. PVR reduction) was less in comparison with the reports from Japan. The potential
explanations offered included the possibility of differences in operability threshold and the variability in
the types of patients treated with BPA between centres.
Although these results of BPA are encouraging, the reports are from expert centres and may not be
generalisable. Even with the technical refinements, there remains a steep learning curve in order to safely,
effectively and consistently perform BPA [68]. A successful BPA requires extensive training and case
experience. BPA should be reserved for expert centres, where it should be considered for symptomatic
TABLE 2 Favourable risk–benefit assessment for pulmonary endarterectomy
Characteristics Lower risk with predictable good long-term outcome Higher risk with less predictable long-term outcome
(not contraindications)
History History of DVT/PE No history of DVT/PE
Examination No signs of right heart failure Signs of right heart failure
Comorbidity None Significant concomitant lung or left heart disease
Functional limitation Functional class II or III Functional class IV
Imaging Clear disease concordant on all images Inconsistency on imaging modalities
Type of disease Bilateral lower lobe disease No disease appreciable in lower lobes
Haemodynamics PVR <1000 dyn·s·cm−5, in proportion to site and number
of obstructions on imaging; higher PA pulse pressure
PVR >1200 dyn·s·cm−5, out of proportion to site and number
of obstructions on imaging; higher PA diastolic pressure
DVT: deep vein thrombosis; PE: pulmonary embolism; PVR: pulmonary vascular resistance; PA: pulmonary artery.
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CTEPH patients ineligible for PEA due to distal chronic thromboembolism or persistent/recurrent PH
after surgery. The role of BPA for those with technically operable disease, but who are unsuitable for
surgery due to subjective determination or patient refusal, has not been established.
BPA patient selection at an expert centre starts with a multidisciplinary review of all available and
pertinent data. Anatomical and functional assessment of pulmonary arteries and lung perfusion are critical
to identify the target vessels [69]. A selective pulmonary angiogram of the target vessels will show more
details and serves as confirmation prior to intervention during BPA. A selective angiogram may not
capture all the distal lesions potentially amenable to BPA, necessitating multiple complementary imaging
modalities such as intravascular imaging and pressure gradient analysis to aid in lesion assessment and
balloon sizing [70].
BPA complications should be defined and uniformly reported. Unlike reperfusion lung injury after PEA
which can be delayed for days before onset [71], the injury associated with BPA appears to be more
vascular injury related to the intervention than the capillary leak syndrome described post-PEA [72].
Table 4 is proposed as a guide for BPA centres for classification of complications. Injury caused by wire
perforation or interruption of the diseased vessel is the most common [69]. Lung injury by wire
perforation or balloon overdilatation in the setting of severe PH risks potentially fatal massive infiltration
and/or haemorrhage which may require mechanical ventilation or extracorporeal support. Classic
reperfusion lung injury is rare with BPA. Published low BPA complications reflect limited experience
confined to experienced BPA centres. In experienced hands, BPA has emerged as a promising and
established treatment for inoperable CTEPH.
PH-targeted medical therapy
While PEA remains the treatment of choice for most patients with CTEPH, around 40% of the patients in
the international CTEPH registry were considered inoperable due to concern for inaccessible vascular
obstruction, PAP out of proportion to morphological lesions and significant prohibitive comorbidities [9].
A large number of small studies and three large randomised controlled trials (table 5) have demonstrated
varying improvements with targeted medical therapy in technically inoperable patients [55, 73, 74].
TABLE 3 University of California San Diego chronic thromboembolism (CTE) surgical
classification
Surgical levels Location of CTE
Level 0 No evidence of thromboembolic disease in either lung
Level I CTE starting in the main pulmonary arteries
(Level IC) (Complete occlusion of one main pulmonary artery with CTE)
Level II CTE starting at the level of lobar arteries or in the main descending pulmonary arteries
Level III CTE starting at the level of the segmental arteries
Level IV CTE starting at the level of the subsegmental arteries
Information from [50].
TABLE 4 Balloon pulmonary angioplasty complications
During the procedure
Vascular injury# with/without haemoptysis
Wire perforation
Balloon overdilatation
High-pressure contrast injection
Vascular dissection
Allergic reaction to contrast
Adverse reaction to conscious sedation/local anaesthesia
After the procedure
Lung injury¶ (radiographic opacity with/without haemoptysis, with/without hypoxaemia)
Renal dysfunction
Access site problems
#: signs of vascular injury: extravasation of contrast, hypoxaemia, cough, tachycardia, increased pulmonary
arterial pressure; ¶: causes of lung injury: vascular injury much greater than reperfusion lung injury.
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However, data are lacking for patients with medical contraindications or those refusing surgery. Riociguat
is the currently approved medical therapy in many countries for inoperable CTEPH based on the CHEST
trials [55, 75]. Recently, the MERIT-1 trial of macitentan in the treatment of inoperable CTEPH showed
improvements of the primary end-point (PVR (p=0.041)) and of other end-points (e.g. 6-min walk
distance (p=0.033) and N-terminal pro-brain natriuretic peptide (p=0.040)) [74]. This last study provided
the first evidence on combination drug therapy in CTEPH. 61% of the included patients were already
treated with phosphodiesterase type 5 inhibitors and/or oral/inhaled prostanoids at inclusion, and addition
of macitentan showed similar efficacy compared with the drug-naive patients. Accordingly, macitentan is
being considered for potential CTEPH registration. Event-driven morbidity/mortality studies have not
been performed in CTEPH.
Patients with persistent/residual post-operative PH were also included in BENEFIT and CHEST-1,
representing around 30% of the study population [55, 73]. Both studies included patients with mPAP
⩾25 mmHg and PVR ⩾300 dyn·s·cm−5 at >6 months after endarterectomy. This can be put in perspective
with real-life data from the large UK national cohort, in which 3–6 months after PEA: 1) 51% of the
patients had mPAP ⩾25 mmHg, 2) mPAP ⩾30 mmHg predicted initiation of PH-targeted medical therapy,
and 3) mPAP ⩾38 mmHg and PVR ⩾425 dyn·s·cm−5 correlated with worse long-term survival [49].
Using medical therapy as a “bridge to PEA” is more controversial, and is felt to delay timely surgical
referral and, therefore, definitive treatment. In the international registry and in a University of California
San Diego cohort, 28% and up to 37%, respectively, of the patients were on some form of PH-targeted
drug(s) at the time of surgical referral [9, 76]. In both cohorts, the delay between diagnosis and surgery
was doubled in the pre-treated patients, without demonstrable clinical benefit. In the international registry,
pre-treatment even independently predicted worse outcome (hazard ratio 2.62; p=0.0072) [48]. Key
limitations of these reports are with inherent referral bias and the possibility of medical therapy potentially
stabilising otherwise deteriorating cases (unknown and not tested). In order to provide the missing
evidence, a phase 2 study will soon commence to include CTEPH patients with high PVR for
pre-operative treatment with riociguat versus placebo (ClinicalTrials.gov identifier NCT0327357). Using
medical therapy as a “bridge to BPA”, although not studied, has become common practice and in keeping
with the indication for riociguat for technically inoperable disease. A study is currently ongoing which
compares riociguat versus BPA for technically inoperable CTEPH, followed by an opportunity to crossover
after 6 months (ClinicalTrials.gov identifier NCT02634203).
CTEPH treatment algorithm
The newly proposed CTEPH treatment algorithm is provided in figure 1 and starts with lifelong
anticoagulation. Antiplatelet therapy is not an alternative to anticoagulation in patients with CTEPH. Data
differentiating the best form of anticoagulation therapy is lacking in CTEPH. Traditional anticoagulation
has been with oral vitamin K antagonists. Whether the newer oral anticoagulants or chronic injectable
anticoagulants are adequate in CTEPH is unknown. The algorithm emphasises the need for a
multidisciplinary assessment, including a surgeon experienced with PEA, PH specialist, BPA
interventionist and CTEPH-trained radiologist. A PH referral centre was previously defined and
recommended as a minimum volume of 50 pulmonary arterial hypertension or CTEPH patients managed
per year [77]. However, given the highly specialised nature of CTEPH treatment, additional factors should
be considered when gauging clinical expertise.
In the CHEST-1 trial, central adjudication exemption and local operability assessment were allowed
provided a participating centre performed more than 20 PEA operations per year [78]. However, the
majority of the operability adjudication occurred with the central committee whose members each
TABLE 5 Pulmonary hypertension-targeted medical therapy randomised controlled trials in chronic thromboembolic
pulmonary hypertension
Trial [ref.] Study drug Duration weeks Subjects n NYHA FC 6MWD m 6MWD effect m PVR baseline dyn·s·cm−5 PVR effect %
BENEFIT [73] Bosentan 16 157 II–IV 342±84 +2NS 783 (95% CI 703–861) −24
CHEST-1 [55] Riociguat 16 261 II–IV 347±80 +46 787±422 −31
MERIT-1 [74] Macitentan 16 (24#) 80 II–IV 352±81 +34 957±435 −16
Data are presented as n or mean±SD, unless otherwise stated. NYHA FC: New York Heart Association Functional Class; 6MWD: 6-min walk
distance; PVR: pulmonary vascular resistance; NS: non-significant. All three trials had an adjudication process for operability. #: 6MWD
measured at 24 weeks.
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performed well in excess of 50 operations per year. In addition, the central adjudication committee had
double the rate of operability determination than the local adjudication committee (15% operable versus
7% operable, respectively). From the international CTEPH registry, a trend with the best in-hospital and
1-year post-operative mortality was observed from centres performing higher volumes of PEA, with the
best results observed from centres performing more than 50 operations per year [79]. This observation
likely does not take into account the relative differences in case complexity, with potentially more
challenging cases referred to higher-volume programmes. Additional emphasis on the importance of
surgical centre experience was reported in the UK national registry of patients undergoing PEA [49]. In
this report, significantly lower in-hospital mortality was observed in the second group of consecutive 500
operated cases compared with the initial group of 500 operated cases. In addition, the ability for
high-volume centres to perform more distal endarterectomy necessitates stratification of surgical centre
expertise [53]. A similar observation applies to BPA success; the safety and efficacy reports of the refined
BPA techniques from Japan are from centres performing the highest volume of procedures (typically more
than 100 per year) [58, 59]. In summary, an expert CTEPH centre should be able to assess and deliver all
established treatment modalities with outcomes similar to or exceeding those published.
Patients with operable CTEPH should receive PEA as the treatment of choice. For those deemed
inoperable, the best level of evidence supports initiating medical therapy and consideration of BPA.
Patients with persistent/recurrent symptomatic PH following PEA should receive medical therapy and be
considered for BPA or re-do endarterectomy in cases of significant re-occlusion [80]. Lastly, given the
subjectivity of operability assessment, it is possible for a patient initially deemed to be inoperable to receive
PEA with or without treatments for inoperable CTEPH. The new algorithm therefore allows for fluidity
between these treatment modalities as information and expertise is gained.
Conclusions
PEA remains the treatment of choice for patients with operable CTEPH. Two additional recognised
treatments are now available (i.e. targeted medical therapy and BPA). A multimodal, individualised
approach to treatment at expert centres integrating surgical, interventional, imaging and medical PH
expertise with the development of clear outcomes analyses is mandatory going forward.
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